Dermatology

dynamic arrows moving up
Biotech

Priovant will move brepocitinib to phase 3 after midstage win

Priovant has presented promising results for potential blockbuster brepocitinib in a rare skin disorder, cutaneous sarcoidosis.
Kevin Dunleavy Feb 6, 2026 7:00am
new york stock exchange
Favicon Fierce Pharma

Veradermics locks in $256M IPO, shares spike

Feb 5, 2026 10:01am
planet hoth ice space sky sun cave cold freezing outerspace

Hoth strikes back against skin toxicities but stock stays frozen

Jan 22, 2026 10:38am
Leo
Favicon Fierce Pharma

JPM26: Leo Pharma sharpens its eye for dermatology dealmaking

Jan 13, 2026 2:45pm
NVS

Novartis pens $1.7B atopic disease pact with British biotech

Dec 9, 2025 3:57am
closed close

Sirona closes R&D labs as Allergan deal, financing plans crumble

Aug 4, 2025 7:55am